Getty Images
Getty Images

Patent filed for new tool in the detection of COVID-19 infection

Embargoed until: Publicly released:
Not peer-reviewed: This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process.

Scientists at the Australian National Phenome Centre have filed a patent that represents a major advance in the detection of COVID-19 infection. The patent involves the use of advanced magnetic resonance technologies to detect the pathological signature of the disease that does not rely on direct detection of the virus.  It also allows long-term effects of the disease to be monitored in a way that will help enable personalised healthcare for long-term COVID-19 sufferers.

Organisation/s: Murdoch University

Funder: Spinnaker Health Research Foundation, WA Government and The McCusker Foundation have contributed to this work.

Media release

From: Murdoch University

Scientists at the Australian National Phenome Centre (ANPC) at Murdoch University in Western Australia have filed a patent that represents a major advance in the detection of COVID-19 infection.

The patent involves the use of advanced magnetic resonance technologies to detect the pathological signature of the disease that does not rely on direct detection of the virus, but on the biological fingerprint the disease has on the patient.

The patent is jointly filed with Bruker Biospin GmbH, a New York Stock Exchange listed company that develops advanced analytical technologies.

Director of the ANPC Professor Jeremy Nicholson said this paved the way to the development of new regulatory approved tests that can be rolled out in multiple countries.

“The new testing paradigm also allows long-term effects of the disease (Long COVID) to be monitored in a way that will help enable personalised healthcare for long-term COVID-19 sufferers,” Professor Nicholson said.

Professor Nicholson said the method identifies new molecular biomarkers linked to abnormal fat biochemistry and the way in which those fats bind to circulating proteins. The novel signatures proved to be highly effective (95% or higher) at distinguishing SARS Cov-2 positive patients from patients with mild to moderate non-COVID-19 respiratory disease.

"The importance of this patent is that it paves the way to developing a regulatory approved test that would be used to help distinguish COVID-19 from other respiratory diseases based on changes in metabolism, not the presence of the virus itself,” Professor Nicholson said.

“An important possible use of this would be to augment existing PCR methods that are a mainstay of border biosecurity protection measures.”

Professor Nicholson said the methods will be developed further over coming months with international partners and regulators in order to create an internationally recognised testing procedure that can be uniformly applied across the world.

"This is an example of an international science collaboration that is driven out of the discoveries of a WA laboratory (the ANPC), effectively with WA leading the COVID-19 diagnostic discovery paradigm," said Professor Nicholson.

"Although WA has been spared the most serious effects of the COVID-19 pandemic so far, there are still many challenges ahead until the population is protected adequately by vaccines or other therapies and biosecurity vigilance, which has worked well in WA so far and must be upheld in the presence of new more aggressive virus variants.”

Professor Nicholson said new physical and chemical methods for detection such as the one proposed will assist in improving screening procedures in the future but are subject to further regulatory refinement and approval which is now ongoing at the ANPC and partner laboratories.

“The test currently works on a small blood plasma sample that requires no pre-treatment and takes about 3-4 minutes per test,” Professor Nicholson said.

"We are further optimising the test procedure for speed and sample size and we expect performance improvements during regulatory development – even though this is still a work-in progress we regard it as a significant translational development" said Professor Nicholson.

Professor Nicholson also acknowledged funding from the Spinnaker Health Research Foundation, WA Government and The McCusker Foundation for supporting the ground-breaking research.

News for:

Australia
International
WA

Media contact details for this story are only visible to registered journalists.